Dexcom vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Diego CGM diabetes technology (NASDAQ: DXCM) ~$3.9B 2024 revenue; G7 prescription CGM market leader, Stelo OTC CGM launched 2024, $75M Oura Ring investment/integration competing with Abbott FreeStyle Libre.
About
Dexcom, Inc. is a San Diego, California-based diabetes management technology company — publicly traded on NASDAQ (NASDAQ: DXCM) as an S&P 500 Health Care component — developing and commercializing continuous glucose monitoring (CGM) systems for people with Type 1 diabetes, Type 2 diabetes, and pre-diabetes through approximately 9,000 employees worldwide. Dexcom's G7 CGM system (a small wearable sensor and transmitter worn on the body that measures glucose continuously every 5 minutes without fingerstick calibration) is the market-leading prescription CGM for insulin-using patients — enabling tight glucose management that prevents hypoglycemic episodes, reduces A1c levels, and improves outcomes for the 8+ million US patients using insulin. In 2024, Dexcom launched Stelo — the first FDA-cleared over-the-counter CGM in the United States, requiring no prescription and targeting the approximately 25 million US adults with Type 2 diabetes who do not use insulin, pre-diabetes patients, and health-conscious consumers seeking metabolic insights. The Stelo OTC CGM integrates with the Oura Ring (wearable health tracking) through a strategic partnership announced in November 2024, with Dexcom investing $75 million in ŌURA and the companies launching Stelo integration in the Oura app — giving users 24/7 glucose insights alongside sleep, heart rate, and activity data from the Oura Ring. Dexcom reported full year 2024 revenue of approximately $3.9 billion, with continued CGM market penetration driving growth.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.